Lineage Cell Therapeutics

Name: Lineage Cell Therapeutics
Address: 2173 Salk Avenue, Suite 200, Carlsbad, CA, 92008, US
Telephone: +15108714188
Price range: Not Applicable

Home
United States
Carlsbad, CA
Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.

05/28/2026

We appreciate Dr. Joe Pantginis for hosting a fireside chat with Brian Culley, CEO of Lineage Cell Therapeutics, as part of H.C. Wainwright & Cos 4th Annual BioConnect Investor Conference at Nasdaq Exchange.

Replay available here: https://bit.ly/3m7EWIp

05/14/2026

We’d like to thank European Pharmaceutical Review for featuring Brian Culley, CEO of Lineage Cell Therapeutics, in its 2026 Cell and Gene Therapy report, where he discusses the potential of scalable, off-the-shelf cell therapies and the manufacturing considerations needed to support broader development.

In the interview, Brian highlights the importance of starting cell therapy development with manufacturing, scale, and control, rather than treating scale-up as a later-stage step.

Read the full report: https://bit.ly/4eMqL8i

05/12/2026

Lineage Cell Therapeutics reported first quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update.

Learn more: https://bit.ly/4nn1p2W

05/05/2026

Lineage Cell Therapeutics announced it will report first-quarter 2026 financial and operating results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update.

For more: https://bit.ly/3P9au2y

05/04/2026

OpRegen® (RG6501) 3-year Phase 1/2a clinical study results in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were presented at Foundation Fighting Blindness’ Retinal Therapeutics Innovation Summit 2026 by Eyal Banin, M.D., Ph.D., Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center Faculty of Medicine, on behalf of Roche and Genentech.

Imaging evidence of structural benefit and greater gains in visual acuity seen in study eyes in Cohort 4 patients (less advanced GA) at month 12, continuing through month 36. Differences as compared with fellow eyes increased over time, suggesting possible modification of the course of disease.

Anatomical and functional improvements occur following a single administration of OpRegen cell therapy.

For more: https://bit.ly/497P4K4

04/30/2026

What will it take for regenerative cell therapy to move from scientific promise to scalable medicine?

In a new interview with Ira S. Pastor of Progress, Potential, And Possibilities, Brian Culley, CEO of Lineage Cell Therapeutics, discusses Lineage’s approach to allogeneic cell therapy and the role of our proprietary AlloSCOPE™ manufacturing platform in supporting off-the-shelf therapies across major unmet needs.

Watch the full interview: https://bit.ly/4cSKBfh

04/14/2026

Please join us in welcoming Priyantha Herath, M.D., Ph.D., to Lineage Cell Therapeutics as Senior Vice President, Head of Clinical.

A board-certified neurologist, Dr. Herath brings extensive experience spanning translational development, regulatory affairs, and clinical development through successful Phase 3 ex*****on. Dr. Herath’s previously held roles at argenx, Alnylam Pharmaceuticals, Voyager Therapeutics, Inc., and Jazz Pharmaceuticals. He received his M.D. with honors from University of Peradeniya and his Ph.D. in Neuroscience from Karolinska Institutet.

For more: https://bit.ly/4t8nWm3

04/13/2026

Lineage Cell Therapeutics has established a Scientific Advisory Board, with Joachim Fruebis, Ph.D., as its founding member.

Dr. Fruebis brings extensive R&D and executive leadership experience across ophthalmology, neurology, diabetes, cardiovascular, metabolic, and rare diseases. His background spans small molecules, biologics, and advanced therapies, with a focus on advancing cell therapy strategies and accelerating drug development.

Most recently, he served as Corporate Vice President, Cell Therapy R&D at Novo Nordisk, and previously held senior leadership roles at BlueRock Therapeutics, Bioverativ, a Sanofi company, Bayer, and Pfizer. He received his Ph.D. and M.S. in Biology from the University Kaiserslautern, Germany, with research conducted at UC San Diego.

For more: https://bit.ly/4t8nWm3

04/09/2026

Lineage Cell Therapeutics thanks San Diego Business Journal for highlighting our expansion into corneal endothelial disease with COR1, targeting a growing global population affected by FECD.

Read the full article: https://bit.ly/4c2QIyF

04/02/2026

Drug discovery is evolving under increasing scientific and operational complexity.

In BioSpace, Brian Culley, CEO of Lineage Cell Therapeutics, shares his perspective on navigating these challenges, including the importance of scalable platforms and aligning innovation with real-world clinical needs.

Read more: https://bit.ly/47AsIQS

Address

2173 Salk Avenue, Suite 200
Carlsbad, CA
92008

Telephone

+15108714188

Website

http://www.lineagecell.com/

Alerts

Be the first to know and let us send you an email when Lineage Cell Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Lineage Cell Therapeutics:

Shortcuts

Want your business to be the top-listed Business in Carlsbad?